Contact Us
Drug Search Results
More Filters [+]

BMS-986397

Alternative Names: bms-986397, bms 986397, bms986397, cc-91633, cc91633, cc 91633
Latest Update: 2024-11-19
Latest Update Note: News Article

Product Description

BMS-986397 is being developed by Bristol-Myer Squibb for the treatment of Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04951778?term=BMS-986397&draw=2&rank=1)

Mechanisms of Action: CK1a Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986397

Countries in Clinic: Australia, Canada, Spain, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CC-91633-AML-001

P1

Recruiting

Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia

2026-05-05

Recent News Events

Date

Type

Title

11/19/2024

News Article

 Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

01/17/2022

News Article

 Global Acute Myeloid Leukaemia Pipeline Landscape Report 2021 - Comprehensive Insights for Approx 150+ Companies and 150+ Pipeline Drugs - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions